A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Panobinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- Acronyms ALPHA-CTCL
- Sponsors Novartis
- 26 Dec 2013 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 17 May 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 13 May 2013 Planned end date changed from 1 Aug 2012 to 1 May 2013 as reported by ClinicalTrials.gov.